CL2011001920A1 - Compuestos derivados biciclicos de 7,8-dihidro[1,2,4]triazolo[4,3-b]piridazina, ligandos del receptor de androgenos; proceso de preparacion; composicion farmaceutica; y su uso para tratar el cancer de prostata. - Google Patents

Compuestos derivados biciclicos de 7,8-dihidro[1,2,4]triazolo[4,3-b]piridazina, ligandos del receptor de androgenos; proceso de preparacion; composicion farmaceutica; y su uso para tratar el cancer de prostata.

Info

Publication number
CL2011001920A1
CL2011001920A1 CL2011001920A CL2011001920A CL2011001920A1 CL 2011001920 A1 CL2011001920 A1 CL 2011001920A1 CL 2011001920 A CL2011001920 A CL 2011001920A CL 2011001920 A CL2011001920 A CL 2011001920A CL 2011001920 A1 CL2011001920 A1 CL 2011001920A1
Authority
CL
Chile
Prior art keywords
triazolo
pyridazine
dihydro
pharmaceutical composition
prostate cancer
Prior art date
Application number
CL2011001920A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Gregory Richard Carr
Alfred Arthur Rabow
Koropoju Srinavasa Rao
Hariksihna Tumma
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2011001920A1 publication Critical patent/CL2011001920A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Compuestos derivados bicíclicos de 7,8-dihidro[1,2,4]triazolo[4,3-b]piridazina, ligandos del receptor de andrógenos; proceso de preparación; composición farmacéutica; y su uso para tratar el cáncer de próstata.
CL2011001920A 2009-02-10 2011-08-09 Compuestos derivados biciclicos de 7,8-dihidro[1,2,4]triazolo[4,3-b]piridazina, ligandos del receptor de androgenos; proceso de preparacion; composicion farmaceutica; y su uso para tratar el cancer de prostata. CL2011001920A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15122109P 2009-02-10 2009-02-10
US18776609P 2009-06-17 2009-06-17

Publications (1)

Publication Number Publication Date
CL2011001920A1 true CL2011001920A1 (es) 2011-10-21

Family

ID=42115693

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001920A CL2011001920A1 (es) 2009-02-10 2011-08-09 Compuestos derivados biciclicos de 7,8-dihidro[1,2,4]triazolo[4,3-b]piridazina, ligandos del receptor de androgenos; proceso de preparacion; composicion farmaceutica; y su uso para tratar el cancer de prostata.

Country Status (27)

Country Link
US (2) US8258140B2 (es)
EP (1) EP2396333B1 (es)
JP (1) JP5059977B2 (es)
KR (1) KR20110113755A (es)
CN (1) CN102388048B (es)
AR (1) AR075383A1 (es)
AU (1) AU2010212590B2 (es)
CA (1) CA2749926A1 (es)
CL (1) CL2011001920A1 (es)
CO (1) CO6410299A2 (es)
CR (1) CR20110427A (es)
CU (1) CU20110158A7 (es)
DO (1) DOP2011000258A (es)
EA (1) EA019647B1 (es)
EC (1) ECSP11011257A (es)
ES (1) ES2427917T3 (es)
HK (1) HK1164870A1 (es)
IL (1) IL214112A0 (es)
MX (1) MX2011008452A (es)
NI (1) NI201100156A (es)
PE (1) PE20120603A1 (es)
SG (1) SG172986A1 (es)
SV (1) SV2011003993A (es)
TW (1) TW201033215A (es)
UY (1) UY32426A (es)
WO (1) WO2010092371A1 (es)
ZA (1) ZA201106625B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120034645A (ko) * 2009-05-11 2012-04-12 아스트라제네카 아베 안드로겐 수용체의 리간드로서 ［１,２,４］트리아졸로［４,３?ｂ］피리다진
CA2856646C (en) 2011-11-30 2020-01-14 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
RS61242B1 (sr) 2012-09-04 2021-01-29 Shanghai hengrui pharmaceutical co ltd Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
NO2719005T3 (es) * 2014-07-28 2018-01-20
CR20170420A (es) 2015-03-13 2017-10-03 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
EP3285764B1 (en) 2015-03-31 2024-03-27 University of Vermont and State Agricultural College Triazolopyridazines for treating cryptosporidiosis
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
US11664093B2 (en) * 2019-01-17 2023-05-30 The Board Of Trustees Of The University Of Illinois Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning
JP7183842B2 (ja) * 2019-02-08 2022-12-06 富士通株式会社 結合自由エネルギー計算の前処理方法、前処理装置及び前処理プログラム、並びに、結合自由エネルギーの算出方法
EP3962907A1 (en) * 2019-05-02 2022-03-09 Constellation Pharmaceuticals, Inc. Modulators of trex1
US20220218701A1 (en) * 2019-05-31 2022-07-14 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods comprising endothelin a receptor antagonists and androgen therapies
TWI813106B (zh) * 2020-12-30 2023-08-21 財團法人工業技術研究院 雄性激素受體結合分子及其用途
IL308122A (en) 2021-06-16 2023-12-01 Celgene Corp Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
US7268230B2 (en) 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
CN1597671A (zh) * 2004-07-20 2005-03-23 贵州大学 喹唑啉衍生物及制备方法和生物活性
AU2005292134B2 (en) * 2004-10-01 2010-12-23 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
AU2006320580B2 (en) * 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
DE602007007734D1 (de) 2006-02-10 2010-08-26 Janssen Pharmaceutica Nv Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren
AU2007215004B2 (en) 2006-02-10 2012-03-01 Janssen Pharmaceutica N.V. Bicyclic imidazole or thiadiazole heterocycles useful as selective androgen receptor modulators
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
JP5238697B2 (ja) 2006-08-04 2013-07-17 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US20100022534A1 (en) * 2006-09-14 2010-01-28 Astrazeneca 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
PT2081937E (pt) * 2006-10-23 2012-10-15 Sgx Pharmaceuticals Inc Moduladores de proteína-cinase de triazolo-piridazina
WO2008109104A1 (en) * 2007-03-07 2008-09-12 The Regents Of The University Of California Bivalent inhibitors of akt protein kinase
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2919870B1 (fr) 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
US8003649B2 (en) * 2007-12-21 2011-08-23 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
KR20120034645A (ko) 2009-05-11 2012-04-12 아스트라제네카 아베 안드로겐 수용체의 리간드로서 ［１,２,４］트리아졸로［４,３?ｂ］피리다진

Also Published As

Publication number Publication date
EP2396333B1 (en) 2013-07-03
HK1164870A1 (en) 2012-09-28
AR075383A1 (es) 2011-03-30
IL214112A0 (en) 2011-08-31
ES2427917T3 (es) 2013-11-04
CU20110158A7 (es) 2012-02-15
KR20110113755A (ko) 2011-10-18
EA201101180A1 (ru) 2012-03-30
DOP2011000258A (es) 2011-09-30
CN102388048B (zh) 2014-07-30
TW201033215A (en) 2010-09-16
WO2010092371A1 (en) 2010-08-19
AU2010212590B2 (en) 2013-01-10
SG172986A1 (en) 2011-08-29
CR20110427A (es) 2011-09-21
US8258140B2 (en) 2012-09-04
ZA201106625B (en) 2013-02-27
EA019647B1 (ru) 2014-05-30
CN102388048A (zh) 2012-03-21
JP5059977B2 (ja) 2012-10-31
SV2011003993A (es) 2012-01-06
ECSP11011257A (es) 2011-09-30
NI201100156A (es) 2012-03-19
AU2010212590A1 (en) 2011-08-04
PE20120603A1 (es) 2012-06-14
CA2749926A1 (en) 2010-08-19
MX2011008452A (es) 2011-12-16
UY32426A (es) 2010-09-30
US20100267699A1 (en) 2010-10-21
EP2396333A1 (en) 2011-12-21
US20130203714A1 (en) 2013-08-08
CO6410299A2 (es) 2012-03-30
JP2012517462A (ja) 2012-08-02

Similar Documents

Publication Publication Date Title
CL2011001920A1 (es) Compuestos derivados biciclicos de 7,8-dihidro[1,2,4]triazolo[4,3-b]piridazina, ligandos del receptor de androgenos; proceso de preparacion; composicion farmaceutica; y su uso para tratar el cancer de prostata.
CL2012001180A1 (es) Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2013000250A1 (es) Compuestos conjugados de dimeros de pirrolo[1,4]benzodiazepina; procedimiento de preparacion; y su uso como agente anticanceroso.
BR112015019508A2 (pt) formas sólidas de um inibidor de cdk4/6 seletivo
CU20120042A7 (es) (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
CL2013003227A1 (es) “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct
NZ711948A (en) Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
CL2012002937A1 (es) Compuestos derivados de 1h-pirrolo[2,3-b]piridina o 7h-pirrolo[2,3-d]pirimidina sustituidos, moduladores de quinasa; composición farmacéutica; kit farmacéutico; método de preparación;y su uso para tratar artritis reumatoide, osteoporosis, alzheimer, cancer pancreatico, cancer de protata y mieloma multiple.
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2014001539A1 (es) Compuestos derivados de pirazolopiridina, inhibidores de los receptores de fgf; proceso para preparar; composición farmaceutica; combinacion farmaceutica; y su uso para tratar y prevenir el cancer, especialmente carcinomas vascularizados tal como de pulmon, mama, prostata, pancreatico, entre otros.
CL2011002812A1 (es) Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata.
UY32275A (es) DERIVADOS DE AZACARBOLINAS 9H-PIRROLO[2,3-b:5,4-c'] DIPIRIDINA, SU PREPARACION Y SU UTILIZACIÓN TERAPÉUTICA.
CL2011002930A1 (es) Compuestos derivados de 8-oxo-9-[3-(1h-bencimidazol-2-iloxi)-fenil]-4,5,6,7,8,9-hexahidro-2h-pirrolo[3,4-b]quinolina-3-carboxilato de etilo; procedimiento de preparacion; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso del compuesto como inhibidor selectivo de quinasas aurora a y b para tratar el cancer.
CL2013000434A1 (es) Compuestos derivados de 6,7-dihidro-3h-oxazolo(3,4) pirazina-5,8-diona, composicion farmaceutica que los comprende; proceso para prepararlos, y uso en el tratamiento de patologias mediadas por inhibicion de la emzima pde-5, como disfuncion erectil, litiasis, hiperplasia prostatica, disfuncion sexual femenia.
MX2013006184A (es) Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
CR20110102A (es) Usos farmacéuticos de lanosta-8,24-dien-3-ols